Company intelligence / Profile preview

Nova Pharmaceutical, Inc.

Maryland, United Statesnova-pharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Nova Pharmaceutical, Inc. was a privately held biotechnology company focused on developing small molecule and peptide therapeutics targeting nervous system diseases such as seizures, psychotic disorders, and pain. As of early 2025, all known drug candidates were in preclinical development. The company was acquired by Galera Therapeutics at the end of 2024.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule drugsSynthetic peptidesChemical drugs
Industry: Biotech

Drug pipeline

1 asset

pan-NOS inhibitor

Phase 1/2

Indications: Metaplastic breast cancer, Triple-negative breast cancer

Beyond the preview

Go deeper on Nova Pharmaceutical, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nova Pharmaceutical, Inc..

Explore the full profile